Emerging roles for cholesterol and lipoproteins in lung disease

Pulmonary Pharmacology and Therapeutics

Volumn 26, Issue 4, 2013, Pages 430-437

  Gowdy, Kymberly M ^a   Fessler, Michael B ^a  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

Cholesterol; Dyslipidemia; Inflammation; Metabolic syndrome; Pulmonary disease; Statins

Indexed keywords

3 [3 [[2 CHLORO 3 (TRIFLUOROMETHYL)BENZYL](2 DIPHENYLETHYL)AMINO]PROPOXY]PHENYLACETIC ACID; ABC TRANSPORTER G1; APOLIPOPROTEIN; APOLIPOPROTEIN E; CHOLESTEROL; CORTICOSTEROID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN; MEVINOLIN; N (2,2,2 TRIFLUOROETHYL) N [4 (2,2,2 TRIFLUORO 1 HYDROXY 1 TRIFLUOROMETHYLETHYL)PHENYL]BENZENESULFONAMIDE; PRAVASTATIN; PURINERGIC P2X RECEPTOR AGONIST; SIMVASTATIN;

ACUTE LUNG INJURY; ADAPTIVE IMMUNITY; ARTICLE; ASTHMA; CARDIOPULMONARY FUNCTION; CELL FUNCTION; CELL MIGRATION; CHOLESTEROL TRANSPORT; DRUG TARGETING; DYSLIPIDEMIA; FIBROSING ALVEOLITIS; GENE TARGETING; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; INNATE IMMUNITY; LUNG ALVEOLUS MACROPHAGE; LUNG DISEASE; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PNEUMONIA; PRIORITY JOURNAL;

ADAPTIVE IMMUNITY; ANIMALS; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL; DISEASE MODELS, ANIMAL; DYSLIPIDEMIAS; HUMANS; IMMUNITY, INNATE; INFLAMMATION; LUNG DISEASES; MICE; RISK FACTORS;

EID: 84880408734     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2012.06.002     Document Type: Article

References (101)

1. Grundy S.M. Inflammation, metabolic syndrome, and diet responsiveness. Circulation 2003, 108:126-128.
2. Kuklina E.V., Yoon P.W., Keenan N.L. Trends in high levels of low-density lipoprotein cholesterol in the United States, 1999-2006. JAMA 2009, 302:2104-2110.
3. Hothersall E., McSharry C., Thomson N.C. Potential therapeutic role for statins in respiratory disease. Thorax 2006, 61:729-734.
4. Hegele R.A. Plasma lipoproteins: genetic influences and clinical implications. Nat Rev Genet 2009, 10:109-121.
5. Lusis A.J. Atherosclerosis Nat 2000, 407:233-241.
6. Lewis G.F., Rader D.J. New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ Res 2005, 96:1221-1232.
7. Grundy S.M. Promise of low-density lipoprotein-lowering therapy for primary and secondary prevention. Circulation 2008, 117:569-573. [discussion 73].
8. Lee J.Y., Parks J.S. ATP-binding cassette transporter AI and its role in HDL formation. Curr Opin Lipidol 2005, 16:19-25.
9. Yvan-Charvet L., Pagler T.A., Wang N., Senokuchi T., Brundert M., Li H., et al. SR-BI inhibits ABCG1-stimulated net cholesterol efflux from cells to plasma HDL. JLipid Res 2008, 49:107-114.
10. Yasuda T., Grillot D., Billheimer J.T., Briand F., Delerive P., Huet S., et al. Tissue-specific liver X receptor activation promotes macrophage reverse cholesterol transport invivo. Arterioscler Thromb Vasc Biol 2010, 30:781-786.
11. Baldan A., Gomes A.V., Ping P., Edwards P.A. Loss of ABCG1 results in chronic pulmonary inflammation. JImmunol 2008, 180:3560-3568.
12. Li Y., Schwabe R.F., DeVries-Seimon T., Yao P.M., Gerbod-Giannone M.C., Tall A.R., et al. Free cholesterol-loaded macrophages are an abundant source of tumor necrosis factor-alpha and interleukin-6: model of NF-kappaB- and map kinase-dependent inflammation in advanced atherosclerosis. JBiol Chem 2005, 280:21763-21772.
13. Yvan-Charvet L., Welch C., Pagler T.A., Ranalletta M., Lamkanfi M., Han S., et al. Increased inflammatory gene expression in ABC transporter-deficient macrophages: free cholesterol accumulation, increased signaling via toll-like receptors, and neutrophil infiltration of atherosclerotic lesions. Circulation 2008, 118:1837-1847.
14. Duewell P., Kono H., Rayner K.J., Sirois C.M., Vladimer G., Bauernfeind F.G., et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 2010, 464:1357-1361.
15. Martinon F., Mayor A., Tschopp J. The inflammasomes: guardians of the body. Annu Rev Immunol 2009, 27:229-265.
16. Tschopp J., Schroder K. NLRP3 inflammasome activation: the convergence of multiple signalling pathways on ROS production?. Nat Rev Immunol 2010, 10:210-215.
17. Rajamaki K., Lappalainen J., Oorni K., Valimaki E., Matikainen S., Kovanen P.T., et al. Cholesterol crystals activate the NLRP3 inflammasome in human macrophages: a novel link between cholesterol metabolism and inflammation. PLoS One 2010, 5. e11765.
18. Freigang S., Ampenberger F., Spohn G., Heer S., Shamshiev A.T., Kisielow J., et al. Nrf2 is essential for cholesterol crystal-induced inflammasome activation and exacerbation of atherosclerosis. Eur J Immunol 2011, 41:2040-2051.
19. Nistor A., Simionescu M. Uptake of low density lipoproteins by the hamster lung. Interactions with capillary endothelium. Am Rev Respir Dis 1986, 134:1266-1272.
20. Hass M.A., Longmore W.J. Regulation of lung surfactant cholesterol metabolism by serum lipopoteins. Lipids 1980, 15:401-406.
21. Kolleck I., Schlame M., Fechner H., Looman A.C., Wissel H., Rustow B. HDL is the major source of vitamin E for type II pneumocytes. Free Radic Biol Med 1999, 27:882-890.
22. Pian M.S., Dobbs L.G. Lipoprotein-stimulated surfactant secretion in alveolar type II cells: mediation by heterotrimeric G proteins. Am J Phys 1997, 273:L634-L639.
23. Bjorkerud S., Bjorkerud B. Lipoproteins are major and primary mitogens and growth promoters for human arterial smooth muscle cells and lung fibroblasts invitro. Arterioscler Thromb 1994, 14:288-298.
24. Vockeroth D., Gunasekara L., Amrein M., Possmayer F., Lewis J.F., Veldhuizen R.A. Role of cholesterol in the biophysical dysfunction of surfactant in ventilator-induced lung injury. Am J Physiol Lung Cell Mol Physiol 2010, 298:L117-L125.
25. McCrae K.C., Weltman B., Alyward S., Shaw R.A., Sowa M.G., Unruh H.W., et al. The effect of elevated dietary cholesterol on pulmonary surfactant function in adolescent mice. Pediatr Pulmonol 2008, 43:426-434.
26. Baritussio A., Enzi G., Inelmen E.M., Schiavon M., de Biasi F., Allegra L., et al. Altered surfactant synthesis and function in rats with diet-induced hyperlipidemia. Metabolism 1980, 29:503-510.
27. Dahl M., Bauer A.K., Arredouani M., Soininen R., Tryggvason K., Kleeberger S.R., et al. Protection against inhaled oxidants through scavenging of oxidized lipids by macrophage receptors MARCO and SR-AI/II. JClin Invest 2007, 117:757-764.
28. Pulfer M.K., Murphy R.C. Formation of biologically active oxysterols during ozonolysis of cholesterol present in lung surfactant. JBiol Chem 2004, 279:26331-26338.
29. Sevanian A., Berliner J., Peterson H. Uptake, metabolism, and cytotoxicity of isomeric cholesterol-5,6-epoxides in rabbit aortic endothelial cells. JLipid Res 1991, 32:147-155.
30. O'Callaghan Y.C., Woods J.A., O'Brien N.M. Comparative study of the cytotoxicity and apoptosis-inducing potential of commonly occurring oxysterols. Cell Biol Toxicol 2001, 17:127-137.
31. Imai Y., Kuba K., Neely G.G., Yaghubian-Malhami R., Perkmann T., van Loo G., et al. Identification of oxidative stress and Toll-like receptor 4 signaling as a key pathway of acute lung injury. Cell 2008, 133:235-249.
32. Wang W., Xu H., Shi Y., Nandedkar S., Zhang H., Gao H., et al. Genetic deletion of apolipoprotein A-I increases airway hyperresponsiveness, inflammation, and collagen deposition in the lung. JLipid Res 2010, 51:2560-2570.
33. Massaro D., Massaro G.D. Apoetm1Unc mice have impaired alveologenesis, low lung function, and rapid loss of lung function. Am J Physiol Lung Cell Mol Physiol 2008, 294:L991-L997.
34. Bates S.R., Tao J.Q., Collins H.L., Francone O.L., Rothblat G.H. Pulmonary abnormalities due to ABCA1 deficiency in mice. Am J Physiol Lung Cell Mol Physiol 2005, 289:L980-L989.
35. Wojcik A.J., Skaflen M.D., Srinivasan S., Hedrick C.C. Acritical role for ABCG1 in macrophage inflammation and lung homeostasis. JImmunol 2008, 180:4273-4282.
36. Thomassen M.J., Barna B.P., Malur A.G., Bonfield T.L., Farver C.F., Malur A., et al. ABCG1 is deficient in alveolar macrophages of GM-CSF knockout mice and patients with pulmonary alveolar proteinosis. JLipid Res 2007, 48:2762-2768.
37. Draper D.W., Madenspacher J.H., Dixon D., King D.H., Remaley A.T., Fessler M.B. ATP-binding cassette transporter G1 deficiency dysregulates host defense in the lung. Am J Respir Crit Care Med 2010, 182:404-412.
38. Draper D.W., Gowdy K.M., Madenspacher J.H., Wilson R.H., Whitehead G.S., Nakano H., et al. ATP binding cassette transporter G1 deletion induces IL-17-dependent dysregulation of pulmonary adaptive immunity. JImmunol 2012.
39. Yao X., Fredriksson K., Yu Z.X., Xu X., Raghavachari N., Keeran K.J., et al. Apolipoprotein E negatively regulates house dust mite-induced asthma via a low-density lipoprotein receptor-mediated pathway. Am J Respir Crit Care Med 2010, 182:1228-1238.
40. Gong H., He J., Lee J.H., Mallick E., Gao X., Li S., et al. Activation of the liver X receptor prevents lipopolysaccharide-induced lung injury. JBiol Chem 2009, 284:30113-30121.
41. Birrell M.A., Catley M.C., Hardaker E., Wong S., Willson T.M., McCluskie K., et al. Novel role for the liver X nuclear receptor in the suppression of lung inflammatory responses. JBiol Chem 2007, 282:31882-31890.
42. Crisafulli C., Mazzon E., Paterniti I., Galuppo M., Bramanti P., Cuzzocrea S. Effects of Liver x receptor agonist treatment on signal transduction pathways in acute lung inflammation. Respir Res 2010, 11:19.
43. Smoak K., Madenspacher J., Jeyaseelan S., Williams B., Dixon D., Poch K.R., et al. Effects of liver X receptor agonist treatment on pulmonary inflammation and host defense. JImmunol 2008, 180:3305-3312.
44. Korf H., Vander Beken S., Romano M., Steffensen K.R., Stijlemans B., Gustafsson J.A., et al. Liver X receptors contribute to the protective immune response against Mycobacterium tuberculosis in mice. JClin Invest 2009, 119:1626-1637.
45. Babiker A., Andersson O., Lindblom D., van der Linden J., Wiklund B., Lutjohann D., et al. Elimination of cholesterol as cholestenoic acid in human lung by sterol 27-hydroxylase: evidence that most of this steroid in the circulation is of pulmonary origin. JLipid Res 1999, 40:1417-1425.
46. Madenspacher J.H., Draper D.W., Smoak K.A., Li H., Griffiths G.L., Suratt B.T., et al. Dyslipidemia induces opposing effects on intrapulmonary and extrapulmonary host defense through divergent TLR response phenotypes. JImmunol 2010, 185:1660-1669.
47. Martens G.W., Arikan M.C., Lee J., Ren F., Vallerskog T., Kornfeld H. Hypercholesterolemia impairs immunity to tuberculosis. Infect Immun 2008, 76:3464-3472.
48. Yeh Y.F., Huang S.L. Dietary cholesterol enhances pulmonary eosinophilic inflammation in a murine model of asthma. Int Arch Allergy Immunol 2001, 125:329-334.
49. Fessler M.B., Massing M.W., Spruell B., Jaramillo R., Draper D.W., Madenspacher J.H., et al. Novel relationship of serum cholesterol with asthma and wheeze in the United States. JAllergy Clin Immunol 2009, 124:967-974. e1-15.
50. McKay A., Leung B.P., McInnes I.B., Thomson N.C., Liew F.Y. Anovel anti-inflammatory role of simvastatin in a murine model of allergic asthma. JImmunol 2004, 172:2903-2908.
51. Yeh Y.F., Huang S.L. Enhancing effect of dietary cholesterol and inhibitory effect of pravastatin on allergic pulmonary inflammation. JBiomed Sci 2004, 11:599-606.
52. Lee J.H., Lee D.S., Kim E.K., Choe K.H., Oh Y.M., Shim T.S., et al. Simvastatin inhibits cigarette smoking-induced emphysema and pulmonary hypertension in rat lungs. Am J Respir Crit Care Med 2005, 172:987-993.
53. Fessler M.B., Young S.K., Jeyaseelan S., Lieber J.G., Arndt P.G., Nick J.A., et al. Arole for hydroxy-methylglutaryl coenzyme a reductase in pulmonary inflammation and host defense. Am J Respir Crit Care Med 2005, 171:606-615.
54. Liu Z.Q., Liu B., Yu L., Wang X.Q., Wang J., Liu H.M. Simvastatin has beneficial effect on pulmonary artery hypertension by inhibiting NF-kappaB expression. Mol Cell Biochem 2011, 354:77-82.
55. Kim J.W., Rhee C.K., Kim T.J., Kim Y.H., Lee S.H., Yoon H.K., et al. Effect of pravastatin on bleomycin-induced acute lung injury and pulmonary fibrosis. Clin Exp Pharmacol Physiol 2010, 37:1055-1063.
56. Myles P.R., Hubbard R.B., McKeever T.M., Pogson Z., Smith C.J., Gibson J.E. Risk of community-acquired pneumonia and the use of statins, ace inhibitors and gastric acid suppressants: a population-based case-control study. Pharmacoepidemiol Drug Saf 2009, 18:269-275.
57. van de Garde E.M., Hak E., Souverein P.C., Hoes A.W., van den Bosch J.M., Leufkens H.G. Statin treatment and reduced risk of pneumonia in patients with diabetes. Thorax 2006, 61:957-961.
58. Chalmers J.D., Singanayagam A., Murray M.P., Hill A.T. Prior statin use is associated with improved outcomes in community-acquired pneumonia. Am J Med 2008, 121:1002-1007. e1.
59. Mortensen E.M., Pugh M.J., Copeland L.A., Restrepo M.I., Cornell J.E., Anzueto A., et al. Impact of statins and angiotensin-converting enzyme inhibitors on mortality of subjects hospitalised with pneumonia. Eur Respir J 2008, 31:611-617.
60. Mortensen E.M., Restrepo M.I., Anzueto A., Pugh J. The effect of prior statin use on 30-day mortality for patients hospitalized with community-acquired pneumonia. Respir Res 2005, 6:82.
61. Schlienger R.G., Fedson D.S., Jick S.S., Jick H., Meier C.R. Statins and the risk of pneumonia: a population-based, nested case-control study. Pharmacotherapy 2007, 27:325-332.
62. Thomsen R.W., Riis A., Kornum J.B., Christensen S., Johnsen S.P., Sorensen H.T. Preadmission use of statins and outcomes after hospitalization with pneumonia: population-based cohort study of 29,900 patients. Arch Intern Med 2008, 168:2081-2087.
63. Majumdar S.R., McAlister F.A., Eurich D.T., Padwal R.S., Marrie T.J. Statins and outcomes in patients admitted to hospital with community acquired pneumonia: population based prospective cohort study. BMJ 2006, 333:999.
64. Cowan D.C., Cowan J.O., Palmay R., Williamson A., Taylor D.R. Simvastatin in the treatment of asthma: lack of steroid-sparing effect. Thorax 2010, 65:891-896.
65. Maneechotesuwan K., Ekjiratrakul W., Kasetsinsombat K., Wongkajornsilp A., Barnes P.J. Statins enhance the anti-inflammatory effects of inhaled corticosteroids in asthmatic patients through increased induction of indoleamine 2, 3-dioxygenase. JAllergy Clin Immunol 2010, 126:754-762. e1.
66. Hothersall E.J., Chaudhuri R., McSharry C., Donnelly I., Lafferty J., McMahon A.D., et al. Effects of atorvastatin added to inhaled corticosteroids on lung function and sputum cell counts in atopic asthma. Thorax 2008, 63:1070-1075.
67. Zeki A.A., Kenyon N.J., Goldkorn T. Statin drugs, metabolic pathways, and asthma: a therapeutic opportunity needing further research. Drug Metab Lett 2011, 5:40-44.
68. Soyseth V., Brekke P.H., Smith P., Omland T. Statin use is associated with reduced mortality in COPD. Eur Respir J 2007, 29:279-283.
69. Blamoun A.I., Batty G.N., DeBari V.A., Rashid A.O., Sheikh M., Khan M.A. Statins may reduce episodes of exacerbation and the requirement for intubation in patients with COPD: evidence from a retrospective cohort study. Int J Clin Pract 2008, 62:1373-1378.
70. Kao P.N. Simvastatin treatment of pulmonary hypertension: an observational case series. Chest 2005, 127:1446-1452.
71. Johnson B.A., Iacono A.T., Zeevi A., McCurry K.R., Duncan S.R. Statin use is associated with improved function and survival of lung allografts. Am J Respir Crit Care Med 2003, 167:1271-1278.
72. Kor D.J., Iscimen R., Yilmaz M., Brown M.J., Brown D.R., Gajic O. Statin administration did not influence the progression of lung injury or associated organ failures in a cohort of patients with acute lung injury. Intensive Care Med 2009, 35:1039-1046.
73. Craig T.R., Duffy M.J., Shyamsundar M., McDowell C., O'Kane C.M., Elborn J.S., et al. Arandomized clinical trial of hydroxymethylglutaryl- coenzyme a reductase inhibition for acute lung injury (The HARP study). Am J Respir Crit Care Med 2011, 183:620-626.
74. Nicholls S.J., Brewer H.B., Kastelein J.J., Krueger K.A., Wang M.D., Shao M., et al. Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial. JAMA 2011, 306:2099-2109.
75. Gutstein D.E., Krishna R., Johns D., Surks H.K., Dansky H.M., Shah S., et al. Anacetrapib, a novel CETP inhibitor: pursuing a new approach to cardiovascular risk reduction. Clin Pharmacol Ther 2012, 91:109-122.
76. Braganza G., Chaudhuri R., McSharry C., Weir C.J., Donnelly I., Jolly L., et al. Effects of short-term treatment with atorvastatin in smokers with asthma-a randomized controlled trial. BMC Pulm Med 2011, 11:16.
77. Barter P.J., Caulfield M., Eriksson M., Grundy S.M., Kastelein J.J., Komajda M., et al. Effects of torcetrapib in patients at high risk for coronary events. NEngl J Med 2007, 357:2109-2122.
78. Delvecchio C.J., Bilan P., Radford K., Stephen J., Trigatti B.L., Cox G., et al. Liver X receptor stimulates cholesterol efflux and inhibits expression of proinflammatory mediators in human airway smooth muscle cells. Mol Endocrinol 2007, 21:1324-1334.
79. Getz G.S., Reardon C.A. Apolipoprotein A-I and A-I mimetic peptides: a role in atherosclerosis. JInflamm Res 2011, 4:83-92.
80. Yao X., Dai C., Fredriksson K., Dagur P.K., McCoy J.P., Qu X., et al. 5A, an apolipoprotein A-I mimetic peptide, attenuates the induction of house dust mite-induced asthma. JImmunol 2011, 186:576-583.
81. Nandedkar S.D., Weihrauch D., Xu H., Shi Y., Feroah T., Hutchins W., et al. D-4F, an apoA-1 mimetic, decreases airway hyperresponsiveness, inflammation, and oxidative stress in a murine model of asthma. JLipid Res 2011, 52:499-508.
82. Van Lenten B.J., Wagner A.C., Anantharamaiah G.M., Garber D.W., Fishbein M.C., Adhikary L., et al. Influenza infection promotes macrophage traffic into arteries of mice that is prevented by D-4F, an apolipoprotein A-I mimetic peptide. Circulation 2002, 106:1127-1132.
83. Zeki A.A., Franzi L., Last J., Kenyon N.J. Simvastatin inhibits airway hyperreactivity: implications for the mevalonate pathway and beyond. Am J Respir Crit Care Med 2009, 180:731-740.
84. Schaafsma D., McNeill K.D., Mutawe M.M., Ghavami S., Unruh H., Jacques E., et al. Simvastatin inhibits TGFbeta1-induced fibronectin in human airway fibroblasts. Respir Res 2011, 12:113.
85. Jacobson J.R., Barnard J.W., Grigoryev D.N., Ma S.F., Tuder R.M., Garcia J.G. Simvastatin attenuates vascular leak and inflammation in murine inflammatory lung injury. Am J Physiol Lung Cell Mol Physiol 2005, 288:L1026-L1032.
86. Van Lenten B.J., Wagner A.C., Navab M., Anantharamaiah G.M., Hui E.K., Nayak D.P., et al. D-4F, an apolipoprotein A-I mimetic peptide, inhibits the inflammatory response induced by influenza A infection of human type II pneumocytes. Circulation 2004, 110:3252-3258.
87. Jiao Y.L., Wu M.P. Apolipoprotein A-I diminishes acute lung injury and sepsis in mice induced by lipoteichoic acid. Cytokine 2008, 43:83-87.
88. Yan Y.J., Li Y., Lou B., Wu M.P. Beneficial effects of ApoA-I on LPS-induced acute lung injury and endotoxemia in mice. Life Sci 2006, 79:210-215.
89. Takahashi S., Nakamura H., Seki M., Shiraishi Y., Yamamoto M., Furuuchi M., et al. Reversal of elastase-induced pulmonary emphysema and promotion of alveolar epithelial cell proliferation by simvastatin in mice. Am J Physiol Lung Cell Mol Physiol 2008, 294:L882-L890.
90. Watts K.L., Sampson E.M., Schultz G.S., Spiteri M.A. Simvastatin inhibits growth factor expression and modulates profibrogenic markers in lung fibroblasts. Am J Respir Cell Mol Biol 2005, 32:290-300.
91. Kim T.H., Lee Y.H., Kim K.H., Lee S.H., Cha J.Y., Shin E.K., et al. Role of lung apolipoprotein A-I in idiopathic pulmonary fibrosis: antiinflammatory and antifibrotic effect on experimental lung injury and fibrosis. Am J Respir Crit Care Med 2010, 182:633-642.
92. Alexeeff S.E., Litonjua A.A., Sparrow D., Vokonas P.S., Schwartz J. Statin use reduces decline in lung function: VA normative aging study. Am J Respir Crit Care Med 2007, 176:742-747.
93. Keddissi J.I., Younis W.G., Chbeir E.A., Daher N.N., Dernaika T.A., Kinasewitz G.T. The use of statins and lung function in current and former smokers. Chest 2007, 132:1764-1771.
94. Frost F.J., Petersen H., Tollestrup K., Skipper B. Influenza and COPD mortality protection as pleiotropic, dose-dependent effects of statins. Chest 2007, 131:1006-1012.
95. Ishida W., Kajiwara T., Ishii M., Fujiwara F., Taneichi H., Takebe N., et al. Decrease in mortality rate of chronic obstructive pulmonary disease (COPD) with statin use: a population-based analysis in Japan. Tohoku J Exp Med 2007, 212:265-273.
96. Mancini G.B., Etminan M., Zhang B., Levesque L.E., FitzGerald J.M., Brophy J.M. Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. JAm Coll Cardiol 2006, 47:2554-2560.
97. Huang C.C., Chan W.L., Chen Y.C., Chen T.J., Chou K.T., Lin S.J., et al. Statin use in patients with asthma: a nationwide population-based study. Eur J Clin Invest 2011, 41:507-512.
98. Menzies D., Nair A., Meldrum K.T., Fleming D., Barnes M., Lipworth B.J. Simvastatin does not exhibit therapeutic anti-inflammatory effects in asthma. JAllergy Clin Immunol 2007, 119:328-335.
99. Ostroukhova M., Kouides R.W., Friedman E. The effect of statin therapy on allergic patients with asthma. Ann Allergy Asthma Immunol 2009, 103:463-468.
100. Nadrous H.F., Ryu J.H., Douglas W.W., Decker P.A., Olson E.J. Impact of angiotensin-converting enzyme inhibitors and statins on survival in idiopathic pulmonary fibrosis. Chest 2004, 126:438-446.
101. Lee T.M., Chen C.C., Shen H.N., Chang N.C. Effects of pravastatin on functional capacity in patients with chronic obstructive pulmonary disease and pulmonary hypertension. Clin Sci (Lond) 2009, 116:497-505.